Business
NeurAxis Reports Strong Fourth Quarter and Full Year 2025 Financial Results
Conference call will be held today, Thursday, March 19 at 9:00 am ETCARMEL, Ind., March 19, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the fourth quarter period and full year ended December 31, 2025. 4Q25 Financial Highlights Revenues increased 27% year over year to $968 thousand in 4Q
About this update from Neuraxis, Inc.
[{"type":"image","alt":"NeurAxis, Inc.","displaySize":"","headline":null,"caption":"NeurAxis, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":89,"url":"https://media.zenfs.com/en/globenewswire.com/53c594c0241aa2985511c98a9154c355"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NUFBfM4lz9bjgdoWOrf8eQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNQ--/https://media.zenfs.com/en/globenewswire.com/53c594c0241aa2985511c98a9154c355","width":300,"height":89}},"lazy":false},{"type":"text","content":"Conference call will be held today, Thursday, March 19 at 9:00 am ET","length":68,"tagName":"p"},{"type":"text","content":"CARMEL, Ind., March 19, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the fourth quarter period and full year ended December 31, 2025.","length":345,"tagName":"p"},{"type":"text","content":"4Q25 Financial Highlights","length":25,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenues increased 27% year over year to $968 thousand in 4Q25.","length":63,"tagName":"p"}]},{"val":[{"type":"text","content":"Operating loss increased 17% year over year, primarily due to higher selling expenses directly related to increased sales volume and compensation expenses to facilitate growth. ","length":177,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash balance was $5.0 million as of December 31, 2025. ","length":54,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":294,"olType":false},{"type":"text","content":"FY2025 Financial Highlights","length":27,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenues for FY2025 increased 33% year over year to $3.6 million.","length":65,"tagName":"p"}]},{"val":[{"type":"text","content":"Operating loss increased 9% year over year, primarily due to a one-time non-recurring legal settlement. Excluding the legal settlement, the Company’s operating loss was flat year over year despite its investment in selling expenses that were offset by higher gross profit from increased sales volume.","length":300,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":365,"olType":false},{"type":"text","content":"Recent Op...